UNLIMITED TURBO SHORT - NOVO-NORDISK B | Market Closed - Euronext Paris 11:50:47 29/05/2024 am IST | ||
| 1.33 EUR | +3.91% |
|
| Current month | -20.50% | ||
| 1 month | -26.01% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 29/24/29 | 1.33 | +3.91% |
| 28/24/28 | 1.28 | +1.59% |
| 27/24/27 | 1.26 | +17.76% |
| 24/24/24 | 1.07 | +9.18% |
| 23/24/23 | 0.98 | -19.67% |
Real-time Euronext Paris
Last update May 29, 2024 at 11:50 am IST
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| MI7MB | |
| ISIN | NLBNPNL2MXU5 |
| Date issued | 31/01/2024 |
| Strike | 995.5 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.34 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.735 € |
|---|---|
| Lowest since issue | 0.98 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
915.7
DKK
Average target price
909.2
DKK
Spread / Average Target
-0.71%
- Stock Market
- Certificates
- MI7MB Certificat
